Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by K Kubota
Total Records ( 3 ) for K Kubota
  Y. H Kim , K Kubota , K Goto , K Yoh , S Niho , H Ohmatsu , N Saijo and Y. Nishiwaki
  Objective

The aim of this study was to determine the maximum-tolerated dose (MTD) and the recommended dose of combination chemotherapy with gemcitabine (GEM) and carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients with a performance status (PS) of 2.

Methods

Chemotherapy-naïve NSCLC patients with PS 2 were enrolled. Chemotherapy consisted of an escalated dose of GEM on days 1 and 8 and CBDCA on day 1 every 3 weeks. Patients were scheduled to receive GEM (mg/m2)/CBDCA (area under the curve: AUC) at four dose levels: 800/4 (level 1), 1000/4 (level 2), 1000/4.5 (level 3) and 1000/5 (level 4), respectively.

Results

Between February 2004 and August 2006, 13 patients were enrolled in this study. Dose-limiting toxicities (DLTs) were thrombocytopenia, febrile neutropenia and hyponatremia. DLTs were observed in two of six patients at dose level 1 and in three of six patients at dose level 2. Dose level 2 was thus determined to be the MTD. Among 12 evaluable patients, 7 patients had stable diseases and 5 patients had progressive diseases, and the median survival time was 3.8 months.

Conclusions

The MTD and the recommended dose for Phase II studies of this regimen were determined to be GEM 1000 mg/m2 and CBDCA AUC of 4. Additional objective measures are needed to evaluate patients’ risk and benefit in future clinical trials for PS 2 patients.

  Y Kono , K Kubota , T Aruga , A Ishibashi , M Morooka , K Ito , J Itami , M Kanemura , S Minowada and T. Tanaka
  Objective

The purpose was to monitor implanted seeds and to determine factors contributing to seed migration after permanent prostate brachytherapy.

Methods

Sixty-two consecutive patients with Stage 1 prostate cancer who underwent brachytherapy with 125I seeds between February 2008 and May 2009 were studied prospectively. On post-operative days 1, 7 and 30, scintigraphy was added to conventional radiography to monitor the migration of the implanted seeds. The prostate volume was measured during the pre-planning stage using ultrasound and during the post-planning stage using computed tomography on post-operative days 0 and 30. Magnetic resonance imaging was performed on day 30.

Results

Of the 4843 seeds implanted in the prostates of 62 patients, 108 seeds (2.2%) in 43 patients (69.4%) exhibited seed migration. Thirty-five seeds could not be identified using any of the imaging modalities and were likely passed during urination (0.7% of the total number of seeds). The maximum number of migrated seeds in one patient was 10 of the 85 implanted seeds. The fraction of patients with seed migration or loss increased from 27.4% on day 1 to 69.4% on day 30. The number of seeds that had migrated from the prostate increased from 48 (0.1% of the total number of seeds) on 1 day to 78 (1.0%) on day 7 and 108 (2.2%) on day 30. Of the seeds lost from the prostate, 38.9% embolized to the lungs. The seed loss during the first post-operative month was closely correlated with the swelling of the prostate gland between the pre-planning measurement and the post-planning measurement performed on day 0 (P < 0.0001).

Conclusions

Prostate swelling between the pre-planning and post-planning (day 0) measurements was significantly associated with seed migration, and adequate attention should be given to this issue.

  D Katagiri , S Masumoto , A Katsuma , E Minami , T Hoshino , T Inoue , M Shibata , M Tada , M Morooka , K Kubota and F. Hinoshita
 

Three patients are reported: two with acute renal failure (ARF) and acute interstitial nephritis (AIN); and one with ARF and rapidly progressive glomerulonephritis (RPGN). In the latter two cases, a percutaneous renal biopsy was performed. In both AIN cases, 2-[18F] fluoro-2-deoxy-D-glucose (FDG) positron emission tomography combined with computed tomography (PET-CT) showed high and diffuse FDG uptake in the renal parenchyma without excretion. Based on the diagnosis of AIN, probable offending drugs were discontinued. Consequently, ARF and AIN recovered gradually in both cases, though haemodialysis (HD) was performed several times. On the other hand, the patient who presented with ARF and RPGN did not accumulate FDG absolutely. Maintenance HD had to be initiated in this patient. FDG-PET-CT might become an auxiliary examination for the diagnosis and follow-up of AIN in oliguric or HD patients.

 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility